DXCM vs JNJ
Based on Invest's signal, Johnson & Johnson (JNJ) currently has the stronger Buy/Hold/Sell rating of the two — a buy versus hold for DXCM.
| Metric | DXCM | JNJ |
|---|---|---|
| Price | $71.54 | $263.40 |
| Day change | +1.5% | +1.6% |
| Market cap | $27.6B | $634.8B |
| P/E ratio | 34.2 | 30.6 |
| 1-year return | -17.2% | +55.8% |
| Invest signal | Hold | Buy |
Higher market cap, higher 1-year return, lower P/E, and a stronger signal are highlighted. Data is for learning, not financial advice.
Can't decide? Trade both — risk-free.
Start with €1,000,000 in virtual cash and practice buying DXCM and JNJ at live prices.
DXCM vs JNJ: FAQ
Is DXCM or JNJ the better stock to buy?
Based on Invest's signal, Johnson & Johnson (JNJ) currently has the stronger Buy/Hold/Sell rating of the two — a buy versus hold for DXCM. Remember that Invest's signal is a data-driven snapshot for learning, not financial advice — the best way to understand the difference is to add both to a watchlist and practice trading them with virtual cash.
Which is bigger, DXCM or JNJ?
Johnson & Johnson is the larger company by market capitalisation ($634.8B vs $27.6B).
Can I practice trading DXCM and JNJ for free?
Yes. Invest is a free stock market simulator — you start with €1,000,000 in virtual cash and can buy and sell both DXCM and JNJ at live market prices, with no real money and no risk. It runs in your browser and as a free iOS app.